Skip to main content
Premium Trial:

Request an Annual Quote

Mondobiotech, 23andMe Team on Rare Disease Research

NEW YORK (GenomeWeb News) — 23andMe and Swiss company Mondobiotech will collaborate to offer researchers information about certain rare genetic diseases, the California consumer genomics firm said today.

The collaboration will use genetic information from individuals who suffer from diseases such as pulmonary arterial hypertension, sarcoidoisis, and pulmonary fibrosis. Mondobiotech will identify these patients and sponsor their enrollment in 23andMe's Personal Genome Service.

23andMe said that it will coordinate genome-wide association studies for Mondobiotech affiliates using its research infrastructure and bioinformatics expertise.

Mondobiotech CEO Fabio Cavalli said in a statement that this collaboration "could go a long way towards understanding the causes of the diseases we have been researching."

Financial terms of the agreement were not released.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.